After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Akebia Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Akebia Therapeutics Inc. is $308.96M. A total of 4.19 million shares were traded on the day, compared to an average of 1.80M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, AKBA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 18 SELLs from insiders. Insiders purchased 1,280,000 shares during that period but sold 432,445.
In the most recent transaction, Butler John P. sold 46,489 shares of AKBA for 1.68 per share on Feb 01. After the transaction, the CEO and President now owns 2,128,883 company shares. In a previous transaction on Feb 01, Burke Steven Keith sold 24,311 shares at 1.68 per share. AKBA shares that SVP, Chief Medical Officer owns now total 711,376.
Among the insiders who sold shares, Dahan Michel disposed of 95,478 shares on May 25 at a per-share price of $1.22. This resulted in the SVP, Chief Operating Officer holding 574,037 shares of AKBA after the transaction. In another insider transaction, Hadas Nicole R. sold 63,186 shares at $1.22 per share on May 25. Company shares held by the SVP, Chief Legal Officer now total 524,344.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for AKBA in the last 3 months, the mean price target is $4.33 with high estimates of $5.00 and low estimates of $4.00. In terms of 52-week highs and lows, AKBA has a high of $1.84 and a low of $0.49.
As of this writing, AKBA has an earnings estimate of -$0.04 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.06. The company reported an EPS of -$0.06 in the last quarter, which was -200.00% lower than expectations of -$0.02.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. AKBA’s latest balance sheet shows that the firm has $149.80M in Cash & Short Term Investments as of fiscal 2021. There were $136.05M in debt and $261.05M in liabilities at the time. Its Book Value Per Share was -$0.21, while its Total Shareholder’s Equity was $74.01M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKBA is Buy with a score of 4.50.
